Equilibre

Equilibre Biopharmaceuticals Corp. is a clinical-stage biopharmaceutical company developing new treatments for patients with neurological disorders. The company's lead candidate, EQU-001, is currently in a large-scale Phase 2 study as an adjunctive therapy for focal epilepsy. EQU-001 is also in multiple preclinical studies for other indications, including seizure prevention in traumatic brain injury, spasticity associated with spinal cord injury, infantile spasms, and MS.